You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,280,959


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,280,959
Title: Metal complexes
Abstract:The invention describes zinc chelated dimeric cell-surface receptor ligands, pharmaceutical compositions containing these compounds, methods of using these compounds as agonist of dimeric cell-surface receptors. Novel processes used in preparing the compounds are also described. Further, the invention describes novel receptor binding moieties of the zinc chelated cell-surface receptor ligands.
Inventor(s): Gleason; John G. (Downingtown, PA), Luengo; Juan I. (Audubon, PA)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:09/530,307
Patent Claims: 1. A method for agonizing dimeric cell-surface receptors in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a zinc chelated dimeric cell-surface receptor ligand.

2. A method for agonizing dimeric cell-surface receptors in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of an organic molecule having a molecular weight from about 100 to about 850, containing of from 1 to 4 zinc binding motifs and provided that each zinc binding motif forms at least two coordinate bonds to a zinc ion.

3. A method for identifying agonists of dimeric cell-surface receptors which comprises contacting the receptor with dimeric cell-surface receptor ligand candidates in the presence of a zinc ion source, and selecting ligand candidates which bind to the receptor.

4. A process for the preparation of a zinc chelated dimeric cell-surface receptor ligand which comprises reacting one or more receptor binding moieties and a zinc ion source followed by optional isolation of the zinc chelated dimeric cell-surface receptor ligand.

5. A zinc chelated cell-surface receptor ligand prepared by the process of claim 4.

6. A zinc chelated cell-surface receptor ligand.

7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 5.

8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 6.

9. A process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent and an effective amount of a compound of claim 5 which process comprises bringing the compound into association with the pharmaceutically acceptable carrier or diluent.

10. A process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent and an effective amount of a compound of claim 6 which process comprises bringing the compound into association with the pharmaceutically acceptable carrier or diluent.

11. An isolated dimeric cell-surface receptor binding moiety of a zinc chelated cell-surface receptor ligand.

12. A dimeric cell-surface receptor binding moiety.

13. The method of claim 1 wherein the cell-surface receptor is the EPO receptor.

14. The method of claim 2 wherein the cell-surface receptor is the EPO receptor.

15. A method for agonizing the EPO receptor in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of claim 11.

16. A method for agonizing the EPO receptor in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of claim 12.

17. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 11.

18. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 12.

19. A process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent and an effective amount of a compound of claim 11 which process comprises bringing the compound into association with the pharmaceutically acceptable carrier or diluent.

20. A process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent and an effective amount of a compound of a compound of claim 12 which process comprises bringing the compound into association with the pharmaceutically acceptable carrier or diluent.

21. A method for agonizing dimeric cell-surface receptors in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of claim 11.

22. A method for agonizing dimeric cell-surface receptors in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of claim 12.

23. A compound of claim 11 for use as an active therapeutic substance.

24. A compound of claim 12 for use as an active therapeutic substance.

25. The method of claim 1 wherein the dimeric cell-surface receptor is the M-CSF receptor.

26. The method of claim 2 wherein the dimeric cell-surface receptor is the M-CSF receptor.

27. A method for agonizing the M-CSF receptor in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of claim 11.

28. A method for agonizing the M-CSF receptor in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of claim 12.

29. The method of claim 1 wherein the dimeric cell-surface receptor is the GRH receptor.

30. The method of claim 2 wherein the dimeric cell-surface receptor is the GRH receptor.

31. A method for agonizing the GRH receptor in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of claim 11.

32. A method for agonizing the GRH receptor in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of claim 12.

33. The method of claim 1 wherein the dimeric cell-surface receptor is the TPO receptor.

34. The method of claim 2 wherein the dimeric cell-surface receptor is the TPO receptor.

35. A method for agonizing the TPO receptor in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of claim 11.

36. A method for agonizing the TPO receptor in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of claim 12.

37. The method of claim 1 wherein the dimeric cell-surface receptor is the leptin receptor.

38. The method of claim 2 wherein the dimeric cell-surface receptor is the leptin receptor.

39. A method for agonizing the leptin receptor in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of claim 11.

40. A method for agonizing the leptin receptor in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of claim 12.

41. The method of claim 1 wherein the dimeric cell-surface receptor is the IFN receptor.

42. The method of claim 2 wherein the dimeric cell-surface receptor is the IFN receptor.

43. A method for agonizing the IFN receptor in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of claim 11.

44. A method for agonizing the IFN receptor in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of claim 12.

45. The method of claim 1 wherein the dimeric cell-surface receptor is the insulin receptor.

46. The method of claim 2 wherein the dimeric cell-surface receptor is the insulin receptor.

47. A method for agonizing the insulin receptor in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of claim 11.

48. A method for agonizing the insulin receptor in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of claim 12.

49. The method of claim 1 wherein the dimeric cell-surface receptor is selected from the TRK receptors.

50. The method of claim 2 wherein the dimeric cell-surface receptor is selected from the TRK receptors.

51. A method for agonizing a selected TRK receptor in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of claim 11.

52. A method for agonizing a selected TRK receptor in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of claim 12.

53. The method of claim 1 wherein said metal chelated dimeric cell-surface receptor ligand comprises a symmetrical multimer of a receptor binding moiety.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.